8-K: Axsome Therapeutics Reveals High Unmet Needs in Narcolepsy Type 1 Patients Despite Treatment

A recent survey by Axsome Therapeutics shows that a significant portion of narcolepsy type 1 patients continue to experience symptoms despite being on treatment.

Summary

• Axsome Therapeutics released the results of the CRESCENDO survey, which focused on the experiences of 203 adult patients with narcolepsy type 1 (NT1).
• The survey, conducted in partnership with Narcolepsy Network, aimed to understand the patient journey, measure disease symptoms, and assess the burden of illness.
• Despite being on treatment, 77% of patients reported experiencing cataplexy, 64% experienced excessive daytime sleepiness (EDS), and 74% exhibited cognitive impairment.
• The most common treatments reported by patients were wake promoting agents (53%), oxybates (47%), and stimulants (42%).
• Additionally, 45% of patients experienced depression and 57% experienced anxiety.
• The survey highlights the significant unmet needs in treated narcolepsy type 1 patients.

Sentiment

Score: 4

Explanation: The document highlights significant unmet needs in narcolepsy treatment, which is a negative finding. However, it also shows Axsome's commitment to addressing these needs, which is a positive. The overall sentiment is slightly negative due to the poor patient outcomes despite treatment.

Positives

• The CRESCENDO survey provides valuable insights into the patient experience with narcolepsy type 1.
• The survey highlights the need for improved treatments for narcolepsy type 1.
• The partnership with Narcolepsy Network ensures a patient-centric approach to the research.
• Axsome plans to present the detailed results of the CRESCENDO survey at upcoming scientific meetings, which will further disseminate the findings.

Negatives

• A large percentage of patients continue to experience significant symptoms despite being on treatment.
• The high rates of cataplexy, excessive daytime sleepiness, and cognitive impairment indicate that current treatments are not fully effective.
• The prevalence of depression and anxiety among patients highlights the psychological burden of the condition.

Risks

• The survey results indicate a significant unmet need in the treatment of narcolepsy type 1, which could impact the market potential for existing and future treatments.
• The company's future success depends on the development of more effective treatments for narcolepsy.
• The company's forward-looking statements are subject to risks and uncertainties, including the success of clinical trials and regulatory approvals.

Future Outlook

Axsome plans to present the detailed results of the CRESCENDO survey at upcoming scientific meetings. The company's future success depends on the development of more effective treatments for narcolepsy and other CNS conditions.

Management Comments

• Dr. Karl Doghramji stated that narcolepsy is underrecognized and underdiagnosed, and the CRESCENDO survey is an important step in raising awareness.
• Axsome is committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians.

Industry Context

The announcement highlights the ongoing challenges in treating narcolepsy, a condition with limited treatment options. This underscores the need for innovative therapies and aligns with the broader industry focus on addressing unmet needs in CNS disorders.

Comparison to Industry Standards

• The high rates of persistent symptoms reported in the CRESCENDO survey, such as 77% experiencing cataplexy and 64% experiencing excessive daytime sleepiness, suggest that current treatments for narcolepsy are not as effective as desired when compared to the goals of complete symptom control.
• While specific comparative data for other narcolepsy patient surveys is not provided in this document, the results indicate a significant gap in treatment efficacy compared to the ideal outcomes.
• The survey results highlight the need for novel therapies that can address the unmet needs of narcolepsy patients, which is a common goal across the pharmaceutical industry.

Stakeholder Impact

• The survey results highlight the need for improved treatments for narcolepsy, which could benefit patients.
• The findings may influence the development of new therapies by Axsome and other pharmaceutical companies.
• The results could also impact the perception of current treatments among healthcare providers and patients.

Next Steps

• Axsome plans to present the detailed results of the CRESCENDO survey at upcoming scientific meetings.

Key Dates

Keywords

narcolepsy, cataplexy, excessive daytime sleepiness, cognitive impairment, CNS disorders, Axsome Therapeutics, CRESCENDO survey, patient survey, unmet needs, sleep disorders